Abstract

This proposal requests continued funding for institutional participation of the Upstate Medical Center, S.U.N.Y., Syracuse, New york, in the clinical research activites of Cancer and Leukemia Group B (CALGB). CALGB is a multi-institutional cooperative research group dedicated to the systematic planning, initiation, conduct, analysis, and reporting of research as applied to therapy of patients with malignant disease. The scope of interest of CALGB and our institutional participation includes the wide variety of malignant disorders. The current CALGB poposal involves and increase in laboratory-based evaluations as well. The program in oncology at the Upstate Medical Center in conjunction with CALGB is a truly interdisciplinary program, involving the active participation of Surgery, Radiotherapy, Clinical Pathology, Psychiatry, Pathology, Cytogenetics and Internal Medicine. The Upstate Medical Center actively participates in all phases of the CALGB program. Our personnel contribute to: group scientific and administrative leadership, new study design and chairmanship, development and execution of pilot studies, the testing of new chemotherapeutic agents in phase I and phase Ii trials in addition to the accrual of greater than 100 patients/year to group-wide phase III and intergroup studies. As a result of the funding provided by this proposal and our institutional commitment, the accrual rate for patients entered into controlled, evaluable, experimental cancer therapy will continue to increase. The broadening and deepening of the clinical research program at our institution will similarly be reflected in the depth and breadth of our scientific and administrative involvement in CALGB activites. Since our institutional participation with CALGB is the core of the interdisciplinary cancer program at our institution, additional salutary effects will continue to be evident in the education of medical students, house officers, nursing staff as well as in the continuing education of physicians in mid New York State. In addition, the collaboration with CALGB will help translate the most recent advances in medical care and expertise to a large and diversified patient population.

  Funding Agency

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Cooperative Clinical Research--Cooperative Agreements (U10)
Project #
5U10CA021060-10
Application #
3556553
Study Section
Cancer Clinical Investigation Review Committee (CCI)
Project Start
1979-04-01
Project End
1988-03-31
Budget Start
1986-04-01
Budget End
1987-03-31
Support Year
10
Fiscal Year
1986
Total Cost
Indirect Cost

  Institution

Name
Upstate Medical University
Department
Type
Schools of Medicine
DUNS #
058889106
City
Syracuse
State
NY
Country
United States
Zip Code
13210

  Publications

Holstein, Sarah A; Jung, Sin-Ho; Richardson, Paul G et al. (2017) Updated analysis of CALGB (Alliance) 100104 assessing lenalidomide versus placebo maintenance after single autologous stem-cell transplantation for multiple myeloma: a randomised, double-blind, phase 3 trial. Lancet Haematol 4:e431-e442
Basch, Ethan; Dueck, Amylou C; Rogak, Lauren J et al. (2017) Feasibility Assessment of Patient Reporting of Symptomatic Adverse Events in Multicenter Cancer Clinical Trials. JAMA Oncol 3:1043-1050
Kohman, Leslie J; Gu, Lin; Altorki, Nasser et al. (2017) Biopsy first: Lessons learned from Cancer and Leukemia Group B (CALGB) 140503. J Thorac Cardiovasc Surg 153:1592-1597
Edelman, Martin J; Wang, Xiaofei; Hodgson, Lydia et al. (2017) Phase III Randomized, Placebo-Controlled, Double-Blind Trial of Celecoxib in Addition to Standard Chemotherapy for Advanced Non-Small-Cell Lung Cancer With Cyclooxygenase-2 Overexpression: CALGB 30801 (Alliance). J Clin Oncol 35:2184-2192
Apoe, Ogheneruona; Jung, Sin-Ho; Liu, Heshan et al. (2016) Effect of Vitamin D Supplementation on Breast Cancer Biomarkers: CALGB 70806 (Alliance) Study Design and Baseline Data. Am J Hematol Oncol 12:4-9
Martin, Linda W; D'Cunha, Jonathan; Wang, Xiaofei et al. (2016) Detection of Occult Micrometastases in Patients With Clinical Stage I Non-Small-Cell Lung Cancer: A Prospective Analysis of Mature Results of CALGB 9761 (Alliance). J Clin Oncol 34:1484-91
Rugo, Hope S; Barry, William T; Moreno-Aspitia, Alvaro et al. (2015) Randomized Phase III Trial of Paclitaxel Once Per Week Compared With Nanoparticle Albumin-Bound Nab-Paclitaxel Once Per Week or Ixabepilone With Bevacizumab As First-Line Chemotherapy for Locally Recurrent or Metastatic Breast Cancer: CALGB 40502/NCCTG N0 J Clin Oncol 33:2361-9
Nwogu, Chukwumere E; D'Cunha, Jonathan; Pang, Herbert et al. (2015) VATS lobectomy has better perioperative outcomes than open lobectomy: CALGB 31001, an ancillary analysis of CALGB 140202 (Alliance). Ann Thorac Surg 99:399-405
Lilenbaum, Rogerio; Samuels, Michael; Wang, Xiaofei et al. (2015) A phase II study of induction chemotherapy followed by thoracic radiotherapy and erlotinib in poor-risk stage III non-small-cell lung cancer: results of CALGB 30605 (Alliance)/RTOG 0972 (NRG). J Thorac Oncol 10:143-7
Heist, Rebecca S; Wang, Xiaofei; Hodgson, Lydia et al. (2014) CALGB 30704 (Alliance): A randomized phase II study to assess the efficacy of pemetrexed or sunitinib or pemetrexed plus sunitinib in the second-line treatment of advanced non-small-cell lung cancer. J Thorac Oncol 9:214-21

Showing the most recent 10 out of 122 publications